Three-year results of a clinical study of prostamol Uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression


Cite item

Full Text

Abstract

Prostamol® Uno (PU) efficacy and safety were studied in a multicenter, open-population, randomized and comparative trial. PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls. The trial evaluated PU action on the symptoms progression and quality of life with application of questionnaires IPSS and QoL (BS). It was found that PU treatment relieved PA symptoms by IPSS, while these symptoms progressed in the controls. QoL improved in the study group and deteriorated in the control one. Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively. Changes in the PSA were not seen and were insignificant, respectively. The results of the study say that prostamol® Uno in a dose 320 mg/day can prevent PA progression without side effects.

References

  1. Guidelines on benign prostatic hyperplasia / de la Rosette J., Alivizatos G., Madersbacher S. et al. European Association of Urology; Brussels, Belgium, 2009.
  2. Jacobsen S. J., Girman C. J., Guess H. A. et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J. Urol. (Baltimore). 1996; 155: 595-600.
  3. McConnell J. D., Bruskewitz R., Walsh P. et al. The effect of fmasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Engl. J. Med. 1998; 338: 557-563.
  4. Roehrborn C. G., Boyle P., Bergner D. et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing fmasteride versus placebo. PLESS Study Group. Urology 1999; 54: 662-669.
  5. Rhodes T., Girman C. J., Jacobsen D. J. et al. Longitudinal prostate volume in a community-based sample: 7 year followup in the Olmsted County Study of urinary symptoms and health status among men. J. Urol. (Baltimore) 2000; 163 (suppl. 4): 249; abstr. 1105.
  6. Медведев А. А. Экстракты Serenoa repens в лечении больных доброкачественной гиперплазией предстательной железы: Дис. ... канд. мед. наук. М.; 2001.
  7. Аляев Ю. Г., Винаров А. З., Локшин К. Л., Спивак Л. Г. Пятилетний опыт лечения Пермиксоном (Serenoarepens, "Pierre Fabre Medicament") больных гиперплазией простаты. Урология 2002; 1: 23-25.
  8. Аляев Ю. Г., Винаров А. З., Локшин К. Л., Спивак Л. Г. Эффективность и безопасность простамола® уно у больных хроническим абактериальным простатитом. Урология 2006; 1: 47-50.
  9. Мазо Е. Б., Дмитриев Д. Г. Клинический эффект применения препарата простамол уно у больных доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2001; 5: 38-41.
  10. Мазо Е. Б., Попов С. В. Простамол уно в длительном и непрерывном лечении больных доброкачественной гиперплазией предстательной железы и хроническим пpocтaтитoм. Pус. мед. журн. 2007; 15 (13).
  11. Трапезникова М. Ф., Дутов В. В., Долгов А. Г. Применение препарата простамол уно в лечении пациентов с доброкачественной гиперплазии простаты и хроническим простатитом. Врач. сословие 2007; 3: 42-43.
  12. Разумов С. В., Деревянко И. И., Сивков А. В. Простамол Уно в лечении больных с доброкачественной гиперплазией предстательной железы. Урология, 2001; 2: 35-37.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies